

1 **Eliminating mother-to-child transmission of HIV in** 2 **Tanzania calls for efforts to address factors associated** 3 **with a low confirmatory test**

4

5

6

7 **Baraka M. Morris^{1*}, Mukome Nyamhagata², Edith Tarimo¹, Bruno Sunguya¹**

8

9 ¹ Muhimbili University of Health and Allied Sciences, P.O. Box 65001, Dar es salaam,

10 Tanzania

11 ² Ministry of Health, P.O. Box 743, Dodoma, Tanzania

12

13 ***Corresponding author**

14 **Email: bamalaki@yahoo.com (BMM)**

15

16

17

18

19

Abstract

Background: Option B+ approach for prevention of mother-to-child transmission (PMTCT) has demonstrated the potential to eliminate pediatric HIV infections. Its success depends on early infant diagnosis (EID) of HIV among the exposed infants within the first 6 weeks, and a subsequent confirmatory HIV test at the 18th month. However, most mothers enrolled in the PMTCT-option B+ cascade of services in Tanzania do not turn-up for such confirmatory tests. We examined factors associated with the turning-up of mother-baby pairs on the PMTCT program for confirmatory HIV testing 18 months post-delivery in Tanzania.

Methods: This study utilized longitudinal data collected between 2015 and 2017 from 751 mother-baby pairs enrolled in the PMTCT- Option B+ approach in 79 health facilities from the 12 regions of Tanzania-mainland. Analysis was conducted using descriptive statistics to characterize the proportion of mother-baby pairs turning up for a confirmatory test and logistic regression analysis to examine factors associated with turning up for a confirmatory HIV testing at the 18th month.

Results: A total of 751 mother-baby records were observed only and 44.2% (95% CI: 40.7 – 47.8) of them received the HIV confirmatory test at 18 months. Mothers aged 25 years or above (adults' mothers) were 1.44 more likely to turn up for confirmatory HIV-testing than young mothers; mothers with partners tested for HIV were 1.74 more likely to have confirmatory HIV-testing compared with partners not tested for HIV; newly HIV-positive mothers diagnosed on enrolment were 28% less likely to turn up their babies for confirmatory HIV-testing compared to known HIV-positive mothers; mothers with treatment supporters were 1.58 more likely to receive confirmatory HIV-testing compared

to mothers without one, and mothers with babies whose DBS-PCR-1 was collected were 3.61 more likely to have confirmatory HIV-testing than those who didn't collect DBS-PCR-1.

Conclusion: This study reveals that the turn-up for confirmatory HIV testing at 18 months among mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. This turn-up is associated with low maternal age, having a male partner who has not tested for HIV, lack of experience with HIV services, lack of treatment supporters, and failure to take the first DBS-PCR HIV test within the first two months post-delivery.

Introduction

The overall risk of HIV transmission from mother-to-child without any intervention ranges from 20% to 45% (Ref). Such unprecedented risk can be ameliorated with a successful implementation of preventing mother-to-child transmission (PMTCT) interventions that includes screening and treatment of both mothers and their newborn. [1-3] Remarkable efforts have been made in scaling up PMTCT services globally. Such efforts have resulted in marked improvement in PMTCT among countries with a heavy burden of HIV/AIDS.[4] Nevertheless, despite marked efforts and investment, the unprecedented burden of new infections still occurs among HIV-exposed newborns globally—Tanzania is no exception. The World Health Organization (WHO) recommended the adoption of universal antiretroviral treatment or Option B+, as the preferred PMTCT approach in LMICs with high HIV prevalence, high fertility, and extended breastfeeding.[2, 5] Under this plan, all women who test HIV positive are enrolled in lifelong ART soon after HIV diagnosis,

regardless of their CD4 count, or HIV clinical stage. The implementation of the Option B+ program requires women and their infants to access HIV care including a PMTCT cascade of HIV prevention services for two years post-delivery.[6] The Option B+ cascade of interventions requires the exposed children to undertake a confirmatory HIV test at 18 months of age to determine whether they are infected. If the child is infected, both the mother and her child are transferred to Care Treatment Clinics (CTC).[5-7]

The adoption and implementation of Option B+ in Tanzania still face several challenges similar to many other sub-Saharan countries. Studies reveal that a significant proportion of women decline the PMTCT service outright, while another group silently defaults from care.[8, 9] The proportion of infants who receive confirmatory HIV tests is also very low. Only 34.6% of babies from HIV-infected mothers are brought for confirmatory HIV testing at 18 months of age.[10] Low turn-up for confirmatory HIV testing denies the opportunity for early diagnosis and treatment among children who might have been infected during breastfeeding. Findings show that most of these undiagnosed children are likely to die before their second birthday if they do not receive treatment.[2, 7, 11]

Evidence on the reasons and causes for low turn-up for confirmatory tests remains inconclusive and varies in Tanzania like in other countries. Thus, this study investigated factors associated with poor turn-up for confirmatory HIV testing at 18 months of age among mother-baby pairs enrolled in the PMTCT Option B+ cascade in Tanzania.

Materials and Methods

Study Design and Population

This secondary analysis study used data from a cohort of mother-baby pairs who received PMTCT care in 79 health facilities in 12 selected regions of Tanzania between 2015-2017. Tanzania approved the National Guidelines for the implementation of Option B+ in 2013. According to this guideline, all pregnant mothers who tested HIV positive were counseled and enrolled in the Option B+ approach where they were monitored from their first antenatal clinic visit until their babies were two years old.[12, 13] Data was collected to monitor and evaluate the adherence to treatment among mother-baby pairs enrolled in the Option B + approach of PMTCT.

Sample Size and sampling

Multistage random sampling was used to select 79 health facilities in the 12 regions of Tanzania mainland for the primary study. In these health facilities, a total of 4,738 HIV-positive mother-baby pairs were enrolled in the Option B+ program from 2015 to 2017. In the current study, only 751 HIV-positive mother-baby pairs were analyzed owing to the completeness of their medical records.

Variables and measures

The outcome variable was the infant's confirmed HIV status at the 18th month of age. The outcome responses were categorical and measured using a nominal scale (dichotomous -

Yes/No), where “Yes” was for mother-baby pairs who turned for confirmatory HIV testing and “No” was for mother-baby pairs who did not turn for confirmatory HIV testing (Lost to Follow up). This did not include babies who died in the course of 18 months.

Independent variables included eight variables. These are: Maternal age groups defined based on the WHO age groups where mothers aged 24 years and less form the young group and those aged 25 years and above from the adult group (2) Gravidity defined as the number of times that a woman has been pregnant. Gravidity was classified into two categories, the first category for mothers in their first & second pregnancies (G1-G2) and the second category for mothers with more than two pregnancies (G3 – max). (3) Gestational age is the measure (usually in weeks) of the age of a pregnancy. Normally, the gestation age is grouped into three groups (trimesters). However, the WHO recommends women start antenatal care in their first trimester. In this study, the gestation age was grouped into two categories, the first category for mothers who were enrolled in their 1st trimesters and the second category for mothers who enrolled in the 2nd and 3rd trimesters. (4) Live with Partner (marital status) measured as a nominal categorical (dichotomous -Yes/No) variable where “Yes” was for married and cohabited mothers and “No” was for Single, divorced, and widowed mothers. (5) Partner tested measured as a categorical variable using a nominal scale (dichotomous -Yes/No), where “Yes” was for mothers with a partner who has tested for HIV and “No” for mothers with a partner who has not tested for HIV (6) Maternal HIV status at enrolment measured as a nominal categorical variable with two groups. The first group was for mothers whose HIV status was already known as HIV positive and the second group was for mothers who were newly diagnosed as HIV positive at enrollment in antenatal care (Known HIV +ve and New HIV +ve). (7) Presence of treatment supporters

was measured dichotomously using a nominal scale. “Yes” was for mothers with treatment supporter(s) and “No” was for mothers without treatment supporter(s). (8) Lastly, Collection of the first dry blood smear (DBS-PCR-1) within the first two months post-delivery. Option B+ PMTCT cascade requires HIV-exposed infants to have their first HIV test within 2 months of age for early HIV diagnosis. For each mother-baby pair it was recorded whether DBS-PCR-1 was collected or not and hence, was measured dichotomously (Yes/No) using a nominal scale.

Loss to Follow-up

Loss to follow-up was one of the child’s final status at the last visit. Likewise, this was one of the observations for not showing up for confirmatory HIV testing at the 18th month age of the baby. However, in this study, we did not analyze the child's last status, because child status is determined at the end of two years.

Data Analysis

The analysis focused on examining the upshots of Option B+ on the compliance to services among mother-baby pairs enrolled in the PMTCT program in Tanzania mainland. Factors associated with poor turn-up for confirmatory HIV testing at 18 months of infant age among these mother-baby pairs were analyzed as well. These factors were placed into four groups namely: maternal social-demographic characteristics (maternal age, gravidity, gestation age at enrolment, and live with a partner), experience with HIV services on enrolment (maternal HIV status), partner involvement on turn-up for confirmatory HIV testing (Partner tested), and presence of treatment supporters (treatment supporter). The

analysis examined whether these factors were associated with turn-up for confirmatory HIV testing.

Data were cleaned and analyzed using the STATA version 15th software package. Measures of central tendency (frequencies, means, medians, and standard deviations) described the socio-demographic characteristics of study participants (HIV-positive mother-baby pairs). A chi-square test of independence was used for the bivariate analysis of the relationships between outcomes and independent categorical variables. A p-value of 0.05 or less was used to determine the significance of the association between predictors and outcome variables. Then the multivariate analysis using multinomial logistic regression analysis was used to determine associations and ascertain the effect of confounders. The backward elimination method was used to determine the final model. First, the model contained all variables that showed significant association with the outcome variable during the bivariate analysis. The least significant variable (the one with the highest p-value) was removed from the model. The elimination continued until the stopping rule was reached. The stopping rule was when all remaining variables had a significant p-value ($P=0.05$).

Ethical Consideration

Ethical clearance for the PMTCT project was obtained from the National Institution of Medical Research (NIMR) and the permission to use mother-baby pairs PMTCT Option B+ cascade data was received from the Ministry of Health, Community Development, Gender, Elderly, and Children, through the PMTCT coordination unit. Informed consent was waived because this was purely secondary data and hence, we did not interact with the

subjects. Confidentiality of participants in the data was highly maintained and special identification numbers were used to ensure anonymity.

Results

General characteristics

The mean age of mothers included in this analysis was 28.9 (SD = 5.8) years. The mean number of pregnancies (gravidity) was 3 ± 2 and the mean gestation age at enrolment was 19.1 ± 6.2 weeks. A total of 502 (78.9%) of 636 mothers who indicated their marital status were living with their partners (i.e. married or cohabited).

Baseline HIV Testing Characteristics of Mother-Baby Pairs

Of the 751 mother-baby records observed, 733 (97.6%, 95% CI: 96.2 – 98.5) had DBS1 collected by 2 months of age but only 332 (44.2%, 95% CI: 40.7 – 47.8) mother-baby pairs received the HIV confirmatory test at 18 months. More than half of 429 (57.1%, 95% CI: 53.5 – 60.6) mothers were newly HIV positive and diagnosed upon enrolment; less than a quarter of 157 (20.9%, 95% CI: 18.1 – 24) mothers had tested partners; and the majority 644 (85.5%, 95% CI: 83.1 – 88.1) of mothers had treatment supporters. (Table 1)

A chi-square test of independence was used to assess the relationship between independent variables and mother-baby pairs HIV confirmatory testing at the 18 months of age

(confirmed HIV testing). There was a significant relationship between the following variables and confirmed HIV testing: maternal age group $\chi^2(1, N = 751) = 6.57, p = 0.01$; gravidity $\chi^2(1, N = 751) = 6.96, p = 0.008$; maternal HIV status at enrollment $\chi^2(1, N = 751) = 4.73, p = 0.03$; partner being tested $\chi^2(1, N = 751) = 7.94, p = 0.005$; collection dried blood spot for *HIV*-1 PCR tested $\chi^2(1, N = 751) = 5.67, p = 0.02$; and presence of treatment supporter tested $\chi^2(1, N = 751) = 4.69, p = 0.03$. There was not a significant relationship between the following variables and confirmed HIV testing: gestation age group at enrolment $\chi^2(1, N = 751) = 3.60, p = 0.06$ and marital status (Live with a partner) $\chi^2(1, N = 636) = 0.06, p = 0.81$. Table 1 below summarizes the results of the descriptive analysis of the baseline HIV testing characteristics of mother-baby pairs

Table 1: The Baseline HIV Testing Characteristics of the 751 Mother-Baby Pairs enrolled in the PMTCT cascade in selected health facilities between 2015 and 2017

Variables		Frequency (%)	95% Conf. Interv	Confirmed HIV - Testing		P-Value
Maternal Age Group	Young (10 – 24)	188 (25)	22.1 – 28.2	120 (63.8)	68 (36.2)	0.010
	Adults (25 – max)	563 (75)	71.7 – 77.9	299 (53.2)	264 (46.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gravidity Groups	G1 – G2	286 (38.1)	34.7 – 41.6	177 (61.9)	109 (38.1)	0.008
	G3 - Max	465 (61.9)	58.4 – 65.3	242 (52.0)	223 (48.0)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gestation Age Group	1 st Trimester	138 (18.4)	15.8 – 21.3	87 (63.0)	51 (37.0)	0.058
	2 nd & 3 rd Trimester	613 (81.6)	78.7 – 84.2	332 (54.2)	281 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Live with Partner	No	134 (21.1)	18.1 – 24.4	76 (56.7)	58 (43.3)	0.814
	Yes	502 (78.9)	75.6 – 81.9	279 (55.6)	223 (44.4)	
	Total	636 (100)		355 (55.8)	281 (44.2)	
Maternal HIV status on Enrolment	Know HIV +ve	322 (42.9)	39.4 – 46.5	165 (51.2)	157 (48.8)	0.030
	New HIV +ve	429 (57.1)	53.5 – 60.6	254 (59.2)	175 (40.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Partner Tested	No	594 (79.1)	76 – 81.8	347 (58.4)	247 (41.6)	0.005
	Yes	157 (20.9)	18.1 – 24	72 (45.9)	85 (54.1)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
DBS1 Collected	No	18 (2.4)	1.5 – 3.8	15 (83.3)	3 (16.7)	0.017
	Yes	733 (97.6)	96.2 – 98.5	404 (55.1)	329 (44.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Treatment Supporter	No	107 (14.3)	11.9 – 16.9	70 (65.4)	37 (34.6)	0.030
	Yes	644 (85.7)	83.1 – 88.1	349 (54.2)	295 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	

Confirmed HIV Testing	No	419 (55.8)	52.2 – 59.3			
	Yes	332 (44.2)	40.7 – 47.8			
	Total	751 (100)				

Factors associated with confirmatory HIV testing among exposed children at 18 months of age

All factors that were statistically significantly associated with the dependent variable were entered into the regression analysis. The binary logistic regression was conducted to provide unadjusted odds ratios. Then multivariate logistic regression was used to obtain an adjusted odds ratio (OR). During the backward elimination method to determine the final model, gravidity and gestation age were not statistically significant and were eliminated consecutively (Table 2).

The results of multiple regression analysis of the factors included in the final model were: Maternal age group adults' mothers were 1.44 more likely to receive confirmatory HIV-testing for their babies than young mothers (Maternal age group AOR=1.44 and p =0.04). Mothers with partners who tested for HIV were 1.74 more times likely to have confirmatory HIV testing than those with partners not tested for HIV (Partner tested AOR=1.74 and p=0.003). New HIV-positive mothers diagnosed on enrolment were 0.72 less likely to turn up their babies for confirmatory HIV-testing than known HIV-positive mothers (Maternal HIV status at enrolment AOR=0.72 and p=0.033); mothers with treatment supporters were 1.58 times more likely to receive confirmatory HIV-testing than mothers without treatment supporters (Treatment supporter AOR=1.58 and p=0.041), and

finally, mothers with babies whose DBS1 was collected were 3.61 more likely to have confirmatory HIV-testing (DBS1 collection AOR=3.61 and p=0.048).

Table 2: Logistic regression analysis of factors associated with turn up for confirmatory among HIV-positive mother-baby pairs who were enrolled in PMTCT cascade in selected health facilities between 2015 and 2017.

Factor	OR	P-Value	95% CI	AOR	P-Value	95% CI
Maternal Age Group	1.56	0.011	1.11 – 2.19	1.44	0.040	1.02 – 2.04
Partner tested	1.66	0.005	1.16 – 2.36	1.74	0.003	1.21 – 2.50
Maternal HIV Status	0.72	0.030	0.54 – 0.97	0.72	0.033	0.53 – 0.97
Treatment Supporter	1.60	0.031	1.04 – 2.45	1.58	0.041	1.02 – 2.46
DBS1 Collected	4.07	0.027	1.17 – 14.18	3.61	0.048	1.01 – 12.84

Discussion

This study provides a picture of the implementation of Option B+ in Tanzania mainly focusing on early infant diagnosis (EID) of HIV among exposed infants. Confirmatory HIV testing is a very important part of EID to ensure that all affected infants are identified and enrolled in treatment. In this study 44.2% of mothers enrolled in Option B+ turned in their babies for confirmatory testing. The study revealed that: Maternal age - adult mothers were more likely to take their babies for confirmatory HIV testing than young mothers, mothers with a tested partner were more likely to take their babies for confirmatory HIV testing than mothers with partners who have not been tested, newly diagnosed mothers were less

likely to take their babies for confirmatory HIV testing than mothers who knew of their HIV status prior to the enrolment (Known HIV positive), mothers with treatment supporters were more likely to take their babies for confirmatory HIV testing than mothers without treatment supporters, and mothers who brought their babies for DBS-PCR-1 collection were more like to take for confirmatory HIV test at the 18-month post-delivery than those mothers who did not bring their babies for DBS-PCR-1 collection.

Lost follow-up is one of the major problems that affect the uptake of confirmatory HIV testing.[14] The implementation of option B+ in Tanzania has remarkably increased the uptake of confirmatory HIV testing at 18 months of age. However, most mothers are still lost to follow-up after the first two months post-delivery. This study showed that 44% of mothers brought their babies for confirmatory HIV testing at the 18th month, which is higher than findings of past studies in Tanzania found only 34.6% of mothers brought their babies to the test.[10, 15] Despite the fact that DBS-CPR 1 collection has been associated with the increase in the uptake of confirmatory HIV testing; still more than 50% of mothers who came for DBS-PCR 1 lost to follow up. The finding is consistent with findings of past studies in Northern Tanzania, which revealed a high loss to follow-up after the first two months post-delivery as one of the setbacks in the implementation of Option B+.[15, 16] Does this have to do with insufficient knowledge about the Option B+ cascade of services until after 18 months? Probably they thought that the DBS-PCR 1 test results were confirmatory and there was no need for another test. Mothers of babies with HIV-negative DBS-PCR 1 results need intensified counseling and close follow-up just like those who test Positive. This will ensure that mother-baby pairs remain in treatment and babies remain HIV-free until they graduate at 18 months.

269

270 Being an adult mother and experienced with PMTCT has been found to increase
 271 compliance to Option B+. Adult mothers (aged 25 years and above) were more likely to
 272 turn up for confirmatory HIV tests at their babies 18 months of age HIV than young
 273 mothers (aged less than 25). The majority of the women in Tanzania have their first
 274 delivery in their youth age.[17] Hence, by the time they reach adulthood age (25 years),
 275 they have experienced reproductive health services and might have been exposed to
 276 PMTCT services thus knowing the importance of adherence to services. Likewise, mothers
 277 who were newly HIV diagnosed (less experienced with PMTCT) were less likely to turn
 278 up for confirmatory HIV test at the 18-month post-delivery than mothers who knew their
 279 HIV status before enrolment to antenatal care (experienced with PMTCT). Studies done in
 280 sub-Saharan Africa have indicated poor adherence to Option B+ among young and newly
 281 HIV-diagnosed mothers.^{3,4} Poor adherence among mothers enrolled in Option B+ has been
 282 found to be associated with a lack of experience with PMTCT services, short time to
 283 process and accept results, denial of the test results, fear of committing to a life-long
 284 treatment regimen, feeling of shame, and stigma.[16, 18]

285 One of the unique findings in this study is that having a partner who has been tested for
 286 HIV is very important for compliance with Option B+ regardless of marital status. While
 287 marital status had no association with mothers turning in their babies for confirmatory HIV
 288 testing; mothers who had their partners tested for HIV are more likely to turn up for
 289 confirmatory HIV tests at their babies 18 months of age. This is contrary to recent studies
 290 in sub-Saharan Africa, which revealed that married mothers were more likely to adhere to
 291 option B+ than unmarried mothers. [19, 20] Awareness of the partner's HIV status has been

associated with compliance with Option B+ services. Studies in Malawi, Ethiopia, and Kenya revealed that mothers who know the HIV status of their partners are more likely to remain in Option B+ care than those who did not know[21]. The finding from this study goes the extra mile as it indicates mothers who know that their partners have tested for HIV regardless of knowledge of their HIV status have an impact on the compliance to Option B+ care. Unfortunately, in this study, less than a quarter of mothers involved in the analysis had their partners tested. The calls for more effort to educate male partners on the importance of HIV testing.

The presence of treatment supporters improves mothers' compliance to Option B+ cascade of services. The majority of mothers involved in this study had a treatment supporter. These findings support studies showing that treatment supporters increase compliance with Option B+.[16, 21-24] A treatment supporter can be a couple, a sibling, a relative, or a friend who a mother has selected to assist. The use of treatment supporters has been a successful technique used in patients with chronic conditions that require long-term course treatment. For instance, treatment supporters have been useful for many years in Tanzania to ensure patients' adherence to the tuberculosis treatment regime.[25, 26] The study conducted Kilimanjaro region on the predictors of postpartum HIV care engagement among women in the PMTCT program, suggested strengthening the social support network system by engaging treatment supporters in HIV care. [13, 16, 18, 27, 28] Therefore, findings from this study cement the importance of engaging treatment supporters not only in engaging mothers to care but also to ensure that their babies receive the

Limitation

This study-employed data from the ministry of health management information system (HMIS) and the PMTCT cascade survey data collected from 80 health facilities. The following limitations were highlighted in this study: Data quality: only 751 of 4738 data collected were complete. This might have affected or influenced some of the results. There is a need to train health workers on the importance of proper documentation, constant supervision, and employ more health workers to cover the shortage. Likewise, these findings are from the analysis of secondary data that were primarily collected from the randomly selected health facilities for routine monitoring activities of PMTCT services. Therefore, it is difficult to know exactly how well the data collection process was done.

Conclusion

This study has found that the turn-up for confirmatory HIV testing at 18 months among mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. More than half of mothers lost to follow-up after the first two months post-delivery. This low turn-up for the confirmatory HIV testing among mother-baby pairs enrolled in the Option B+ approach is associated with low maternal age (young mothers), the low uptake of HIV testing among male partners (having a male partner who has not tested for HIV), being a newly diagnosed HIV mother (lack of experience to HIV services), lack of treatment supporters, and failure to take the first DBS-PCR HIV test within the first two months post-delivery. These factors have to be addressed in the Option B+ implementation guidelines in order to increase the retention of mother-baby pairs into the Option+ B cascade of services.

Recommendations for future directions

The study recommends the following: Post-HIV testing counseling sessions among young mothers (mothers under 25 years of age) and newly HIV-diagnosed mothers be intensified; male partner involvement in reproductive services, couple counseling, and the importance of HIV result disclosure should be enhanced; and further studies be done to identify the best modalities of identifying, integrating and utilizing treatment supporters who will assist HIV infected mother to comply Option B+ cascade,

Reference:

1. UNAIDS U. Countdown to ZERO: global plan towards the elimination of new HIV infections among children by 2015 and keeping their mother alive: UNAIDS; 2011.
2. UNAIDS. 2015 progress report on the global plan towards the elimination of new HIV infections among children and keeping their mothers alive. 2015.
3. Muyunda B, Musonda P, Mee P, Todd J, Michelo C. Effectiveness of lifelong ART (Option B+) in the prevention of mother-to-child transmission of HIV programme in Zambia: observations based on routinely collected health data. *Frontiers in public health*. 2020;7:401.
4. Kak L, Chitsike I, Luo C, Rollins N. Prevention of mother-to-child transmission of HIV/AIDS programmes. Opportunities for Africa's newborns: Practical data, policy and programmatic support for newborn care in Africa: WHO; 2011. p. 113-26.
5. AVERT. Prevention of mother-to-child transmission (PMTCT) of HIV 2017 [cited 2018]. Available from: <https://www.avert.org/professionals/hiv-programming/prevention/prevention-mother-child>.

- 359 6. Gamell A, Luwanda LB, Kalinjuma AV, Samson L, Ntamatungiro AJ, Weisser M,
360 et al. Prevention of mother-to-child transmission of HIV Option B+ cascade in rural
361 Tanzania: The One Stop Clinic model. PloS one. 2017;12(7):e0181096.
- 362 7. MoHCDGEC. Tanzania Elimination of Mother to Child Transmission of HIV
363 Strategic Plan II 2018 – 2021. Dar es Salaam: MoHCDGEC; 2017.
- 364 8. Kalua T, Tippet Barr B, van Oosterhout J, Mbori-Ngacha D, Schouten E, Gupta S,
365 et al. Lessons Learned From Option B+ in the Evolution Toward “Test and Start” From
366 Malawi, Cameroon, and the United Republic of Tanzania. Acquir Immune Defic Syndr.
367 2017;75(Suppl 1):S43-S50.
- 368 9. McLean E, Renju J, Wamoyi J, Bukonya D, Ddaaki W, Church K, et al. ‘I wanted
369 to safeguard the baby’: a qualitative study to understand the experiences of Option B+ for
370 pregnant women and the potential implications for ‘test-and-treat’ in four sub-Saharan
371 African settings. Sex Transm Infect. 2017;93(Suppl 3).
- 372 10. Samson S, Mpembeni RN, Njau PF, Kishimba RS. Uptake of early infant diagnosis
373 (EID) at six weeks after cessation of breastfeeding among HIV exposed children: A cross
374 sectional survey at six high volume health facilities in Iringa, Tanzania. Journal of
375 Interventional Epidemiology and Public Health. 2018;1(10).
- 376 11. MoHSW T. National Guidelines for Comprehensive Care Services for Prevention
377 of Mother-to-Child Transmission of HIV and Keeping Mothers Alive. In: Programme NP,
378 editor. Dar es Salaam, Tanzania: MoHSW, Tanzania; 2013.
- 379 12. UNAIDS. 2015 PROGRESS REPORT ON THE GLOBAL PLAN
380 towards the elimination of new HIV infections among children and keeping their mothers
381 alive. 2015.

382 13. Atanga P. Retention-in-Care, Adherence and Treatment outcomes in a cohort of
383 HIV- positive pregnant and breastfeeding women enrolled in a pilot project implementing
384 “Option B+” in Cameroon.: Medical Centre of the University of Munich (LMU); 2016.

385 14. Gumede-Moyo S, Filteau S, Munthali T, Todd J, Musonda P. Implementation
386 effectiveness of revised (post-2010) World Health Organization guidelines on prevention
387 of mother-to-child transmission of HIV using routinely collected data in sub-Saharan
388 Africa: a systematic literature review. *Medicine*. 2017;96(40).

389 15. Cichowitz C, Mazuguni F, Minja L, Njau P, Antelman G, Ngocho J, et al.
390 Vulnerable at each step in the PMTCT care cascade: high loss to follow up during
391 pregnancy and the postpartum period in Tanzania. *AIDS and Behavior*. 2019;23(7):1824-
392 32.

393 16. Mazuguni F, Mwaikugile B, Cichowitz C, Watt MH, Mwanamsangu A, Mmbaga
394 BT, et al. Unpacking loss to follow-up among HIV-infected women initiated on option B+
395 in Northern Tanzania: a retrospective chart review. *EA Health Research Journal*.
396 2019;3(1):6-15.

397 17. Ministry of Health CD G, Elderly, Children MoHMZ NBoS. Tanzania
398 demographic and health survey and malaria indicator survey (TDHS-MIS) 2015–16.
399 MoHCDGEC, MoH, NBS, OCGS, and ICF Dar es Salaam, Tanzania, and Rockville,
400 Maryland, USA. 2016.

401 18. Watt MH, Cichowitz C, Kisigo G, Minja L, Knettel BA, Knippler ET, et al.
402 Predictors of postpartum HIV care engagement for women enrolled in prevention of
403 mother-to-child transmission (PMTCT) programs in Tanzania. *AIDS care*.
404 2019;31(6):687-98.

405 19. Lencha M. Adherence to option B+ and associated factors among pregnant women
406 on PMTCT Services at Public Health Facilities of east Shawa zone, Oromia, Ethiopia. J
407 Womens Health Reprod Med. 2018;2(1):2.

408 20. Flax VL, Hamela G, Mofolo I, Hosseinipour MC, Hoffman IF, Maman S. Factors
409 influencing postnatal Option B+ participation and breastfeeding duration among HIV-
410 positive women in Lilongwe District, Malawi: A qualitative study. PloS one.
411 2017;12(4):e0175590.

412 21. Asefa EY, Dirirsa DE. Level of Good Adherence on Option B+ PMTCT and
413 Associated Factors Among HIV Positive Pregnant and Lactating Mothers in Public Health
414 Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State, Southwestern
415 Ethiopia, 2018. HIV/AIDS (Auckland, NZ). 2020;12:789.

416 22. Yeshialem Asefa E, Edosa Dirirsa D. Level of Good Adherence on Option B+
417 PMTCT and Associated Factors Among HIV Positive Pregnant and Lactating Mothers in
418 Public Health Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State,
419 Southwestern Ethiopia, 2018. HIV AIDS (Auckl). 2020;12:789-98. doi:
420 10.2147/HIV.S283184. PubMed PMID: 33273864.

421 23. Wondimu F, Yetwale F, Admassu E, Binu W, Bulto GA, Lake G, et al. Adherence
422 to Option B+ Care for the Prevention of Mother-to-Child Transmission Among Pregnant
423 Women in Ethiopia. HIV/AIDS (Auckland, NZ). 2020;12:769.

424 24. Kisigo GA, Ngocho JS, Knettel BA, Oshosen M, Mmbaga BT, Watt MH. “At
425 home, no one knows”: A qualitative study of retention challenges among women living
426 with HIV in Tanzania. Plos one. 2020;15(8):e0238232.

25. Mkopi A, Range N, Lwilla F, Egwaga S, Schulze A, Geubbels E, et al. Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania. *PloS one*. 2012;7(12):e51828.
26. Mkopi A, Range N, Amuri M, Geubbels E, Lwilla F, Egwaga S, et al. Health workers' performance in the implementation of Patient Centred Tuberculosis Treatment (PCT) strategy under programmatic conditions in Tanzania: a cross-sectional study. *BMC health services research*. 2013;13(1):1-7.
27. Atanga PN. Retention-in-care, adherence and treatment outcomes in a cohort of HIVpositive pregnant and breastfeeding women enrolled in a pilot project implementing "Option B+" in Cameroon: *Imu*; 2017.
28. Atanga PN, Ndetan HT, Achidi EA, Meriki HD, Hoelscher M, Kroidl A. Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV-positive women initiating 'Option B+' in the South West Region. *Tropical Medicine & International Health*. 2017;22(2):161-70.